Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634721 | 0.83 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL25365781 | 0.83 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL29920885 | 0.67 | L3MBTL1 (0.41) | L3MBTL1MEN1KMT2A | |
| SCHEMBL23835077 | 0.67 | L3MBTL1 (0.41) | L3MBTL1MEN1KMT2A | |
| SCHEMBL8046949 | 0.66 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL25365349 | 0.64 | L3MBTL1 (0.37) | L3MBTL1MEN1KMT2A | |
| SCHEMBL31751259 | 0.64 | L3MBTL1 (0.34) | L3MBTL1MEN1KMT2A | |
| SCHEMBL25366255 | 0.63 | PARP1 (0.36) | — | |
| SCHEMBL436526 | 0.62 | TSHR (0.45) | L3MBTL1MEN1KMT2A | |
| SCHEMBL7979466 | 0.62 | MEN1 (0.37) | L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177408-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Etern Therapeutics Hongkong Limited (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4484420-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023155927-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海奕拓医药科技有限责任公司 | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177408-A1 | INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | YAP1, YES1, TEAD2 | L3MBTL1 1895/4885MEN1 2682/4885KMT2A 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.